http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors, according findings to be presented by Fox Chase Cancer Center researchers at the AACR Annual Meeting 2013 on Tuesday, April 9. http://medicalxpress.com/news/2013-04-treatment-resistant-lung-cancer.html Cancer Tue, 09 Apr 2013 09:40:24 EST news284719217 (HealthDay)—A simple blood test might help predict a pancreatic cancer patient's chances of benefiting from chemotherapy, a small study suggests. http://medicalxpress.com/news/2013-01-blood-pancreatic-cancer-treatment.html Cancer Wed, 23 Jan 2013 16:20:01 EST news278177531 (HealthDay)—For patients with advanced lung cancer, prompting oncologists via e-mail successfully improved both the rate and timing of outpatient code status documentation in patients' electronic health records, according to research published online Jan. 2 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2013-01-e-mail-prompts-code-status-documentation.html Cancer Sat, 05 Jan 2013 10:40:13 EST news276604806 Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab (Pac+Cb+B) in patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC), according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago. http://medicalxpress.com/news/2012-09-standard-chemotherapy-higher-survival-experimental.html Cancer Thu, 06 Sep 2012 15:04:23 EST news266162654 Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago. http://medicalxpress.com/news/2012-09-adding-bavituximab-second-line-chemotherapy-response.html Cancer Thu, 06 Sep 2012 13:40:30 EST news266157617 (HealthDay) -- In older patients with mantle-cell lymphoma, a rituximab-based chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) followed by maintenance therapy with rituximab improves survival, according to a study published in the Aug. 9 issue of the New England Journal of Medicine. http://medicalxpress.com/news/2012-08-r-chop-benefits-older-mantle-cell-lymphoma.html Cancer Thu, 09 Aug 2012 12:30:01 EST news263731579 (HealthDay) -- Zaltrap (ziv-afilbercept) has been approved by the U.S. Food and Drug Administration in combination with a FOLFIRI chemotherapy regimen for adults with advanced metastatic (spreading) colorectal cancer, the agency said Friday. http://medicalxpress.com/news/2012-08-zaltrap-advanced-colorectal-cancer.html Medications Sat, 04 Aug 2012 06:30:01 EST news263278092 (HealthDay) -- Treatment of children with newly-diagnosed T-cell acute lymphoblastic leukemia (T-ALL) with nelarabine, in addition to an intensive Berlin-Frankfurt-Münster (BFM) 86-based chemotherapy regimen, is feasible and safe, according to a study published online June 25 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-06-nelarabine-chemo-viable-children-t-cell.html Cancer Fri, 29 Jun 2012 15:17:11 EST news260201823 Magnetic resonance imaging (MRI) provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination, according to a new study published online in the journal Radiology. http://medicalxpress.com/news/2012-05-breast-mri-chemotherapy-effectiveness.html Cancer Wed, 23 May 2012 04:40:02 EST news256966083 Analysis of a drug regimen approved by the F.D.A. in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients age 65 years and older who received this regimen did not have improved survival compared to patients who received the standard treatment of carboplatin and paclitaxel alone, according to a study in the April 18 issue of JAMA, a theme issue on comparative effectiveness research. http://medicalxpress.com/news/2012-04-drug-regimen-treatment-non-small-cell.html Cancer Tue, 17 Apr 2012 10:51:03 EST news253878657 The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4. The results also revealed that increases in interleukin-8 levels early after treatment with pazopanib may predict a lack of tumor response to the therapy. http://medicalxpress.com/news/2012-04-biomarker-drug-response-refractory-urothelial.html Cancer Sun, 01 Apr 2012 06:05:21 EST news252479112 The largest study ever on the effect of genetic variability on the toxicity of chemotherapy in breast cancer shows that it is possible to predict which patients are most likely to suffer serious side effects, a researcher will tell the 8th European Breast Cancer Conference (EBCC-8) today (Friday). Dr. Christof Vulsteke, from the Catholic University of Leuven, Belgium, will explain how his team's research is an important step towards achieving a personalised chemotherapy regime for each patient. http://medicalxpress.com/news/2012-03-individual-genetic-variation-chemotherapy-side.html Cancer Fri, 23 Mar 2012 03:51:35 EST news251693480 Researchers found that CYFRA and change in levels of CYFRA were found to be reliable markers for response to chemotherapy for non-small cell lung cancer (NSCLC) in a study of 88 patients. Research presented in the April 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology shows that this marker can be used to determine whether or not a patient should continue a particular chemotherapy regimen. http://medicalxpress.com/news/2012-03-cyfra21-marker-advanced-nsclc.html Cancer Thu, 15 Mar 2012 12:22:30 EST news251032932 (HealthDay) -- The prevalence of older people with cancer using complementary medications as they start a chemotherapy regimen is 17 percent, and is associated with less advanced disease and higher functional status, according to a study published online Feb. 22 in Cancer. http://medicalxpress.com/news/2012-03-complementary-meds-percent-elderly-cancer.html Cancer Fri, 02 Mar 2012 12:42:01 EST news249914514 In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy treatment. Two new studies are published today on these drugs. One published by The Lancet Oncology, showing lapatinib to be less beneficial than trastuzumab for single-agent therapy, and one by The Lancet showing that combining both drugs appears almost twice as effective as single-agent therapy (although lapatinib causes more side-effects). http://medicalxpress.com/news/2012-01-role-lapatinib-trastuzumab-her2-positive.html Cancer Mon, 16 Jan 2012 18:30:01 EST news245930332 New research led by the NCIC Clinical Trials Group (CTG) at Queen's University has proven patients with limited stage Hodgkin's lymphoma have a better chance of long-term survival if they undergo a standard chemotherapy regimen as opposed to radiation-based treatment. http://medicalxpress.com/news/2011-12-survival-chemotherapy-patients-limited-stage-hodgkin.html Cancer Mon, 12 Dec 2011 11:50:02 EST news242912202 A first-of-its kind study led by Xiao-Cheng Wu, MD, MPH, Associate Professor of Public Health at LSU Health Sciences Center New Orleans, reports that a significant number of women are not receiving guideline-recommended treatment for breast cancer and what factors contribute. The research is published online in the Journal of Clinical Oncology December 5, 2011 Early Release section. http://medicalxpress.com/news/2011-12-women-breast-cancer-adjuvant-treatment.html Cancer Tue, 06 Dec 2011 11:43:08 EST news242394179 Younger patients with diffuse large B-cell lymphoma given a more intensive regimen of chemotherapy combined with rituximab survive significantly longer, and are approximately twice as likely to remain in remission 3 years later, compared with patients given standard chemotherapy treatment plus rituximab, according to an article published Online First in the Lancet. http://medicalxpress.com/news/2011-11-intensive-chemotherapy-recurrence-survival-younger.html Cancer Thu, 24 Nov 2011 18:30:03 EST news241362774 A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan. http://medicalxpress.com/news/2011-04-phase-trial-benefit-atrasentan-added.html Cancer Thu, 21 Apr 2011 12:54:39 EST news222609267